Literature DB >> 3693521

Tumor necrosis factors alpha and beta in acquired immunodeficiency syndrome (AIDS) and aids-related complex.

A J Ammann1, M A Palladino, P Volberding, D Abrams, N L Martin, M Conant.   

Abstract

Human immunodeficiency virus (HIV) infection is associated with abnormalities of both T-cell and B-cell immunity in patients with acquired immunodeficiency syndrome (AIDS). Previous studies demonstrated deficient production of the cytokines interleukin-1 (IL-1), interleukin-2 (IL-2), and gamma interferon (IFN-gamma). Tumor necrosis factor alpha and tumor necrosis factor beta have not been previously investigated in AIDS. In this study we demonstrate that peripheral blood mononuclear cells from patients with HIV infection who have either AIDS-related complex or acquired immunodeficiency syndrome are deficient in the production of tumor necrosis factor alpha and tumor necrosis factor beta. These cytokines, derived predominantly from monocytes or lymphocytes, respectively, function as immunoregulatory, antitumor, and antiinfective proteins. A deficiency in their production may therefore be responsible for many of the complications associated with HIV infection in patients with AIDS-related complex or acquired immunodeficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3693521     DOI: 10.1007/bf00915059

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  27 in total

1.  Lymphotoxin production in AIDS.

Authors:  N H Ruddle
Journal:  Immunol Today       Date:  1986-01

2.  The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin.

Authors:  S H Lee; B B Aggarwal; E Rinderknecht; F Assisi; H Chiu
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

Review 3.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

4.  Increase of vulnerability to lymphotoxin in cells infected by vesicular stomatitis virus and its further augmentation by interferon.

Authors:  D Aderka; D Novick; T Hahn; D G Fischer; D Wallach
Journal:  Cell Immunol       Date:  1985-05       Impact factor: 4.868

5.  Elevated beta 2-microglobulin and lysozyme levels in patients with acquired immune deficiency syndrome.

Authors:  M H Grieco; M M Reddy; H B Kothari; M Lange; E Buimovici-Klein; D William
Journal:  Clin Immunol Immunopathol       Date:  1984-08

6.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

7.  Patients with abnormal proportions of T-lymphocyte subsets have reduced in vitro cellular immunity.

Authors:  D S Chudwin; M J Cowan; D W Wara; A J Ammann
Journal:  Clin Immunol Immunopathol       Date:  1983-01

8.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  11 in total

Review 1.  The immunocompromised host: HIV infection.

Authors:  James M Beck
Journal:  Proc Am Thorac Soc       Date:  2005

2.  Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNF-alpha is related to a higher cytotoxic activity.

Authors:  D Hober; A Haque; P Wattre; G Beaucaire; Y Mouton; A Capron
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

3.  Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.

Authors:  S K Sambhi; M R Kohonen-Corish; I A Ramshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

4.  Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens.

Authors:  M Denis; E Ghadirian
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

5.  In vitro and in vivo induction of tumor necrosis factor alpha by Borrelia burgdorferi.

Authors:  D L Defosse; R C Johnson
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide.

Authors:  J R Munis; D D Richman; R S Kornbluth
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

7.  Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages.

Authors:  P D Smith; S S Saini; M Raffeld; J F Manischewitz; S M Wahl
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 8.  Abnormalities in host defense associated with HIV infection.

Authors:  James M Beck
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

9.  Tumor necrosis factor alpha production in schistosomiasis with carcinoma of urinary bladder.

Authors:  S Raziuddin; M Masihuzzaman; S Shetty; A Ibrahim
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

10.  Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients.

Authors:  H F Havas; R S Axelrod; M M Burns; D Murasko; M Goonewardene
Journal:  Med Oncol Tumor Pharmacother       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.